Physician profile
James A Maliszewski
NPI 1902897903
$2,439.29
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $551 · 2021: $1,205.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $312.02 | 2019-2021 | |
| Abbvie INC. | $289.95 | 2019-2021 | |
| Amgen INC. | $277.62 | 2019-2021 | |
| Lilly USA, LLC | $211.98 | 2019-2021 | |
| Foundation Medicine, INC. | $202.16 | 2021 | |
| Novo Nordisk INC | $178.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $101.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $97.02 | 2019-2021 | |
| Eisai INC. | $86.60 | 2020-2021 | |
| Astellas Pharma US INC | $79.62 | 2019-2020 | |
| Abbott Laboratories | $62.28 | 2021 | |
| Glaxosmithkline, LLC. | $61.23 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $55.73 | 2019-2021 | |
| Janssen Biotech, INC. | $52.97 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $49.58 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.97 | 2019-2021 | |
| Sanofi Pasteur INC. | $36.23 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $25.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.29 | 2019-2021 | |
| Allergan, INC. | $24.76 | 2020 | |
| Amarin Pharma, INC. | $18.87 | 2019 | |
| Phadia US INC. | $16.17 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.68 | 2021 | |
| Boston Scientific Corporation | $15.52 | 2021 | |
| Ucb, INC. | $14.41 | 2020 | |
| Medtronic Vascular, INC. | $12.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.49 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Maliszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.